Erin Catherine Carter - 31 Dec 2023 Form 4 Insider Report for Glucotrack, Inc. (GCTK)

Role
Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Issuer symbol
GCTK
Transactions as of
31 Dec 2023
Net transactions value
+$179,665
Form type
4
Filing time
31 Mar 2025, 07:52:53 UTC
Previous filing
11 Sep 2023
Next filing
07 Oct 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GCTK Common Stock, par value $0.001 per share Award $0 +903 $0.000000 903 31 Dec 2023 Direct
transaction GCTK Common Stock, par value $0.001 per share Award $0 +458 +51% $0.000000 1,361 08 Apr 2024 Direct
transaction GCTK Common Stock, par value $0.001 per share Conversion of derivative security $64,834 +2,078 +153% $31.20 3,439 14 Nov 2024 Direct F3
transaction GCTK Common Stock, par value $0.001 per share Exercise of in-the-money or at-the-money derivative security $0 +40,297 +1172% $0.000000 43,736 12 Mar 2025 Direct F5
transaction GCTK Common Stock, par value $0.001 per share Award $0 +1,896 +4.3% $0.000000 45,632 26 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GCTK Convertible Promissory Note Purchase $50,000 $50,000 18 Jul 2024 Common Stock, par value $0.001 per share 1,603 $31.20 Direct F1, F2
transaction GCTK Convertible Promissory Note Conversion of derivative security $64,831 0 14 Nov 2024 Common Stock, par value $0.001 per share 2,078 $31.20 Direct F1, F2, F3
transaction GCTK Series A Common Warrant Award +2,078 2,078 14 Nov 2024 Common Stock, par value $0.001 per share 2,078 $5.60 Direct F4
transaction GCTK Series B Common Warrant Award +2,078 2,078 14 Nov 2024 Common Stock, par value $0.001 per share 40,297 $5.60 Direct F4
transaction GCTK Series B Common Warrant Exercise of in-the-money or at-the-money derivative security $0 -2,078 -100% $0.000000 0 12 Mar 2025 Common Stock, par value $0.001 per share 40,297 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $50,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date").
F2 If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price").
F3 On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into common stock, par value $0.001 per share (the "Common Stock") at the Floor Price.
F4 On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").
F5 On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney Note: On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's common stock, par value $0.001 per share (the "Common Stock") was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "2025 Reverse Split," and together with the 2024 Reverse Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.